Here's Why Bausch Health Stock Gained 14.7% in a Week
BHC stock rises 14.7% in a week after a report surfaced that the company is in talks with Jefferies Financial Group to push out maturities on some of its debt.
Opinion
Op-ed: Here’s why a sale of Bausch + Lomb could lead to a windfall for Bausch Health investors
Hedge fund managers sit on the boards of Bausch Health and Bausch + Lomb. They don’t think like your typical corporate board, writes Ken Squire of 13D Monitor.
Bausch + Lomb’s stock soars 14% on report company is considering selling itself
The stock of eyecare company Bausch + Lomb Corp. was up 18% early Monday, after the Financial Times reported that the company is considering selling itself as a way to extricate itself from its indebted parent.
Bausch Health Taps Jefferies to Refinance Debt, Aid Spinoff
Bausch Health Cos. is working with Jefferies Financial Group to explore refinancing some of its debt to aid a long-planned spinoff of its stake in the eye-care company Bausch + Lomb, according to people with knowledge of the situation.
Bausch + Lomb reportedly exploring sale to handle Bausch Health spinoff
Bausch + Lomb (BLCO) stock will be in focus as company is exploring a sale to address concerns raised over its separation from Bausch Health (BHC). Read mroe here.
Bausch + Lomb soars on report that it’s exploring a sale
A sale could value Bausch + Lomb at more than $13 billion, according to Bloomberg Intelligence analyst Mike Holland. The news is “certainly welcome to investors tied up in the Gordian’s knot at Bausch Health today, both on the equity and credit sides,” Holland said.
Bausch + Lomb Shares Up in Premarket Amid Sale Consideration
Bausch + Lomb rose in premarket trading Monday after the Financial Times reported that it is considering selling itself as a way to separate from Bausch Health, its indebted parent company. Shares traded nearly 16% higher in New York at $18.02.
Bausch + Lomb Stock Jumps Amid Reports Of A Sale
Key Takeaways Bausch + Lomb is discussing a possible sale that would separate it from its parent company, Bausch Health Cos.Bausch Health is saddled with debt of $21 billion, nearly $10 billion of which is set to mature in 2027.
Bausch & Lomb gains after report of PE interest in takeover
Bausch & Lomb (NYSE:BLCO) rose 1.8% in premarket trading after a report about private equity interest in a takeover of the eyecare company. Private equity firms including Blackstone (BX), Advent International,
Sale Rumors Lift Both Bausch + Lomb And Parent Bausch Health - A Breakthrough Is Likely
Bausch Health is rumored to be looking to sell its Bausch + Lomb business, which will ease bankruptcy concerns and upgrade ...
The Financial Times6d
Private equity suitors line up for Bausch + Lomb eyecare auction
Bausch + Lomb was put up for sale after a planned separation from its parent company Bausch Health, formerly known as ...
Buy Rating Reaffirmed for Bausch Health on Prospective Bausch + Lomb Sale and Value Unlocking
Analyst Glen Santangelo of Jefferies reiterated a Buy rating on Bausch Health Companies (BHC – Research Report), reducing the price ...
Bausch & Lomb Sues Competition Over Copycat Formulation and 'Confusingly Similar' Product Name
This suit was surfaced by Law.com Radar, ALM's source for immediate alerting on just filed cases in state and federal courts.
Bausch & Lomb And Edgewise Therapeutics Are Among Top 7 Mid Cap Stock Gainers Last Week (Sept 15-Sept 21): Are The Others In Your Portfolio?
Federal Reserve's rate cut boosted tech, construction, industrial, machinery, and financial sectors. Top-performing mid-cap ...